(Q30574065)

25 June 2017

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data (English)

1 reference

25 June 2017

1 reference

M H A Rustin

1

1 reference

PubMed ID

23082810

25 June 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

British Journal of Dermatology

25 June 2017

1 reference

25 June 2017

167 Suppl 3

1 reference

25 June 2017

3-11

1 reference

The risk of mortality in patients with psoriasis: results from a population-based study

25 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

The long-term efficacy and safety of new biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Risk-benefit assessment of methotrexate in the treatment of severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Teratogenicity of high vitamin A intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11208.X

10.1111/J.1365-2133.2012.11208.X

21 January 2018

Identifiers

DOI

1 reference

release_arvd74ihlvf3tceermc73jynoq

25 June 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/arvd74ihlvf3tceermc73jynoq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23082810

1 reference

PubMed ID

23082810